Open-label study in patients with partial lipodystrophy-associated NASH featured in oral presentation
News
Recent Press Releases
April 4, 2017
March 31, 2017
Vancouver, British Columbia, March 31, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corrigan will serve as a member of the compliance committee.
March 15, 2017
- Company Reiterates FY 2017 Total Net Product Sales Expected to be
Between $155 and $165 million - Global Expansion Plans for Metreleptin Opportunity Underway